No article text was recorded for this version.
disproportionality analysis
Version 2 of 264 papers81 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Safety of antidepressants commonly used in 6–17-year-old children and adolescents: A disproportionality analysis from 2014–2023 on the basis of the FAERS database
- Blog: Liver injury in children: signal analysis of suspected drugs based on the food and drug administration adverse event reporting system
- Blog: Detect Adverse Drug Reactions for Drug Aspirin
- Blog: Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system
- Blog: Detect Adverse Drug Reactions for Drug Atorvastatin
- Blog: Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems
- Blog: Pharmacovigilance insights into drug-associated venous thromboembolism
- Blog: A Real‐World Pharmacovigilance Study of Fruquintinib Based on the <scp>FDA</scp> Adverse Event Reporting System ( <scp>FAERS</scp> ) Database
- Blog: Detecting adverse drug reactions for the drug Simvastatin
- Blog: Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA Adverse Event Reporting System Database
- Blog: Navigating the complex landscape of benzodiazepine- and Z-drug diversity: insights from comprehensive FDA adverse event reporting system analysis and beyond
- Blog: Immune Checkpoint Inhibitors-related Myocarditis in Patients With Cancer: an Analysis of International Spontaneous Reporting Systems
- Blog: Early Detection of Adverse Drug Reactions in Social Health Networks: A Natural Language Processing Pipeline for Signal Detection
- Blog: Cardiovascular adverse events associated with targeted therapies for multiple myeloma: a pharmacovigilance study
- Blog: Detect adverse drug reactions for the drug Pravastatin
- Blog: Comparative safety signals of dopamine agonists: psychiatric and cardiovascular risks derived from FDA adverse event reporting system (FAERS) data
- Blog: Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system
- Blog: Risk of Congenital Anomalies Associated with Psychotropic Medications: A Review of Neonatal Reports in the FDA Adverse Event Reporting System (FAERS)
- Blog: Real-World pharmacovigilance analysis of drug-related conjunctivitis using the FDA adverse event reporting system database
- Blog: Foundational Model-aided Automatic High-throughput Drug Screening Using Self-controlled Cohort Study
- Blog: Pharmacovigilance study on old drugs repurposed for rare diseases across different indications: the case of fenfluramine
- Blog: Comparison of algorithms that detect drug side effects using electronic\n healthcare databases
- Blog: A Network Analysis of Drug Combinations Associated with Acute Generalized Exanthematous Pustulosis (AGEP)
- Blog: Decoding Ambrisentan's Risks: A Deep Dive into FAERS Data
- Blog: Generalized enrichment analysis improves the detection of adverse drug events from the biomedical literature
- Blog: Mesenteric Artery Dissection Aneurysm Associated with Apatinib in a Prostate Cancer Patient: A Case Report and Literature Review
- Blog: Adverse drug events associated with tiotropium: a real-world pharmacovigilance study of FDA adverse event reporting system database
- Blog: Comprehensive analysis of adverse events associated with onasemnogene abeparvovec (Zolgensma) in spinal muscular atrophy patients: insights from FAERS database
- Blog: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
- Blog: Adverse events reporting of edaravone: a real-world analysis from FAERS database
- Blog: A curated and standardized adverse drug event resource to accelerate drug safety research
- Blog: Learning the Relationships between Drug, Symptom, and Medical Condition Mentions in Social Media
- Blog: Drug-associated serotonin syndrome in elderly patients: a comprehensive disproportionality analysis based on the FAERS database
- Blog: Post-marketing risk analysis of bendamustine: a real-world approach based on the FAERS database
- Blog: Comparison of algorithms that detect drug side effects using electronic healthcare databases
- Blog: The real-world safety profile of empagliflozin: a disproportionality analysis based on the FDA Adverse Event Reporting System (FAERS) database
- Blog: Population-scale identification of differential adverse events before and during a pandemic
- Blog: Similarity‐Based Modeling Applied to Signal Detection in Pharmacovigilance
- Blog: Investigating the Detection of Adverse Drug Events in a UK General Practice Electronic Health-Care Database
- Blog: Real-world database evaluation of drug-associated vitreous opacities and machine learning for clinical interpretability
- Blog: Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database
- Blog: A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database
- Blog: Signal mining and analysis of trifluridine/tipiracil adverse events based on real-world data from the FAERS database
- Blog: Detect adverse drug reactions for drug Pioglitazone
- Blog: A discovery and verification approach to pharmacovigilance using electronic healthcare data
- Blog: Standardizing adverse drug event reporting data
- Blog: Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
- Blog: Medical Fraud and Abuse Detection System Based on Machine Learning
- Blog: Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
- Blog: Drug-associated infections and infestations in older adults with tumor necrosis factor-alpha inhibitors: a real-world retrospective and pharmacovigilance study
- Blog: Comparing drug safety of hepatitis C therapies using post-market data
- Blog: Adverse reactions of immune checkpoint inhibitors combined with Proton pump inhibitors: a pharmacovigilance analysis of drug-drug interactions
- Blog: The International Conference on Intelligent Biology and Medicine 2019: computational methods for drug interactions
- Blog: Comparability of clinical trials and spontaneous reporting data regarding COVID-19 vaccine safety
- Blog: Investigating the Detection of Adverse Drug Events in a UK General Practice Electronic Health-Care Database
- Blog: Efficacy and safety and analysis of thrombopoietin receptor agonists for the treatment of immune thrombocytopenia in adults: analysis of a systematic review and network meta-analysis of randomized controlled trials and results of real-world safety data
- Blog: Osteoporotic fractures: an unrecognized adverse event of immune checkpoint inhibitors?
- Blog: Annotation Analysis for Testing Drug Safety Signals using Unstructured Clinical Notes
- Blog: Identifying Candidate Risk Factors for Prescription Drug Side Effects\n using Causal Contrast Set Mining
- Blog: The Impact of Tirzepatide on Cancer Development: a literature review
Showing 60 of 64 papers.
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_disproportionality_analysis_9ccec1e1,
title = {disproportionality analysis},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/disproportionality-analysis/rdr_9ccec1e18a0045e0a8ebc7a8164b3136},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}This exact version (version 2, frozen text):
@misc{lacuna_disproportionality_analysis_9ccec1e1_v2,
title = {disproportionality analysis},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/disproportionality-analysis/rdr_9ccec1e18a0045e0a8ebc7a8164b3136/v/2},
note = {Version 2, frozen 2026-10-04. Accessed 2026-11-20},
}